The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma
Reinhard Dummer(University Hospital of Zurich), Michael R. Migden(The University of Texas MD Anderson Cancer Center), Ragini R. Kudchadkar, Alexander Guminski(The University of Sydney), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Uwe Trefzer(Goethe University Frankfurt), R. M. Herd(New South Wales Department of Primary Industries), Manisha Mone, Anne Lynn S. Chang(Stanford University), Ruth Plummer(National Health Service), Céline Pallaud(Novartis (Switzerland)), Dalila Sellami(Daiichi Sankyo (United States)), P. Combemale(Centre Léon Bérard), Luc Dirix(European Organisation for Research and Treatment of Cancer), Carmen Loquai(Johannes Gutenberg University Mainz), Tingting Yi(Army Medical University), John T. Lear(Salford Royal Hospital), Sven Gogov(Novartis (Switzerland)), Martin Kaatz(SRH Wald-Klinikum Gera), Frank Cornélis(Cliniques Universitaires Saint-Luc), Alexander Stratigos(National and Kapodistrian University of Athens), H. J. Schulze(Fachklinik Hornheide), Karl D. Lewis(University of Colorado Denver)
Cited by 163
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k